A carregar...
Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries
PURPOSE: Novel parenteral (bortezomib) and oral (lenalidomide) therapies have improved survival in myeloma, but the standard Medicare benefit covers only parenteral drugs. We examined the association between prescription drug coverage, receipt of therapy, and survival among Medicare beneficiaries wi...
Na minha lista:
| Publicado no: | J Clin Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Clinical Oncology
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6366642/ https://ncbi.nlm.nih.gov/pubmed/30113885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.77.8894 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|